MedTrace Logo

Safety and Efficacy Study of Bimatoprost in Japanese Patients With Chemotherapy-Induced Eyelash Hypotrichosis

NCT01391286 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 36

Last updated 2019-07-08

Study results available
· View outcomes & findings →

Summary

This study will evaluate the safety and efficacy of bimatoprost solution 0.03% compared with vehicle in Japanese adults with hypotrichosis of the eyelashes following chemotherapy treatment.

Conditions

  • Eyelash Hypotrichosis

Interventions

DRUG

bimatoprost solution 0.03%

One drop of bimatoprost solution 0.03% applied along each upper eyelid margin once daily in the evening for 4 months.

DRUG

bimatoprost vehicle solution

One drop of bimatoprost vehicle solution applied along each upper eyelid margin once daily in the evening for 4 months.

Sponsors & Collaborators

  • Allergan

    lead INDUSTRY

Principal Investigators

  • Medical Director · Allergan

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
20 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2011-07-01
Primary Completion
2012-05-25
Completion
2012-05-25

Countries

  • Japan

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01391286 on ClinicalTrials.gov